

# Programme

25 november 2025, Amsterdam  
KIT Royal Tropical Institute

## Session 1: Through the Looking Glass: Future Needs in HIV Treatment and Prevention

Chairs: Anna Roukens (LUMC) & prof.dr. Marc van der Valk (Board Stichting NCHIV)

10:00 - 10:10	Opening and introductions	<b>Maximazaal</b>
10:10 - 10:45	(Digital) Plenary "Antiretroviral Therapy in 2025 and beyond" and Q&A	Board Stichting NCHIV dr. José Arribas (La Paz University Hospital Madrid)
10:45 - 10:55	Summary SHM monitoring report	Ard van Sighem (SHM)
10:55 - 11:05	Short presentations - Risk of a new HIV diagnosis and determinants for PrEP non use before diagnosis - Insights from phylogenetics - Gaps in the HIV care continuum"	Vita Jongen (SHM) Daniela Bezemer (SHM) Vita Jongen (SHM)
11:05 - 11:30	Panel discussion Panellists: Jorian van Schagen (Bestuurslid PrEP nu) Dr. Sarah Stutterheim (Associate Professor, Maastricht University) Paul Zantkuijl (Strategic advisor Key Populations, Soaa Aids Nederland) Dr. Henrieke Prins (head STD clinic, GGD Utrecht)	Moderators: prof.dr. Marc van der Valk (Board Stichting NCHIV) & Anna Roukens (LUMC)
11:30 - 12:00	<b>Refreshment break</b>	<b>Marble Hall</b>

## Session 2: Parallel oral abstract sessions

Chairs: Judith Branger (Flevoziekenhuis) & Casper Rokx (Erasmus MC)	<b>Maximazaal</b>	Chairs: Janneke van de Wijgert (UMC Utrecht) & Brooke Nichols (AIGHD)	<b>Mauritszaal</b>	Chairs: Leanne Helgers (Amsterdam UMC) & Jéssica dos Santos (Radboudumc)	<b>Raadzaal</b>			
<b>CLINICAL &amp; SOCIOBEHAVIOURAL SCIENCE</b>		<b>EPIDEMIOLOGY &amp; PUBLIC HEALTH</b>		<b>BASIC &amp; TRANSLATIONAL SCIENCE</b>				
12:00 - 12:10	O.01 Discontinuing PrEP, why and what next? – An exploration of why European MSM stop taking PrEP, how they continue to protect themselves from HIV and who is being left behind	Johann Kolstee (Maastricht University)	12:00 - 12:10	O.07 Evaluating the impact and effectiveness of HIV testing strategies among men who have sex with men in the Netherlands	Alexandra Teslya (UMC Utrecht)	12:00 - 12:10	O.13 Siglec-1 functions as a sensor inducing innate and adaptive immunity to HIV-1	Bart Grijmans (Amsterdam UMC)
12:10 - 12:20	O.02 Applying structural topic modelling based on machine learning to empower qualitative research: Perceptions of long-acting injectable PrEP among MSM in the Netherlands and Belgium based on Dutch open-ended responses	Haoyi Wang (Maastricht University)	12:10 - 12:20	O.08 Identifying where HIV self-screening yields the greatest impact: insights from routine data in South Africa	Alexandra De Nooy (AIGHD)	12:10 - 12:20	O.14 HIV-Associated Sex Differences in the Plasma Proteome Associate with Reservoir Size and CVD risk	Suzanne Ruijten (Radboudumc)
12:20 - 12:30	O.03 Development, validation, and real-world implementation of a rapid diagnostic assay for the screening of non-suppressible viremia in people with HIV-1	Jolanda Voermans (Erasmus MC)	12:20 - 12:30	O.09 Changes in condomless anal sex and HIV and STI incidence among men who have sex with men over a period of 15 years: findings from the prospective Amsterdam Cohort Studies	Carien Blomaard (GGD Amsterdam)	12:20 - 12:30	O.15 Sc-SQuHIVLa: Advancing HIV-1 Reservoir Quantification Through Single-Cell In Situ RT-LAMP Amplification and Flow Cytometric Detection	Zora Sinay (Erasmus MC)
12:30 - 12:40	O.04 Nurse-directed same-day initiation of cART: high feasibility and more rapid virologic control using a uniform algorithm	Maaïke Kok (OLVG)	12:30 - 12:40	O.10 HIV Prevention Pathways Among Individuals Who Discontinued PrEP at the Center for Sexual Health Amsterdam: Might They Still Benefit from PrEP?	Inge Willemstein (GGD Amsterdam)	12:30 - 12:40	O.16 TRIM24 acts as an HIV-1 restriction factor and is a potential target for latency reversal	Charlotte Verkuijlen (Amsterdam UMC)
12:40 - 12:50	O.05 People with HIV with major ECG abnormalities have a significantly higher risk of incident CVD compared to people without HIV	Manon Vanbellighen (Amsterdam UMC)	12:40 - 12:50	O.11 Impact of the termination of the Dutch PrEP pilot on community pharmacy dispensing patterns	Piter Oosterhof (OLVG)	12:40 - 12:50	O.17 Latency Promoting Agents as Experimental Tools and Block-and-Lock Candidates in HIV Cure Research	Anniek Tanja (UMC Utrecht)
12:50 - 13:00	O.06 Incidence of community-acquired pneumonia and herpes zoster in people with HIV based on CD4-count and age in the current antiretroviral therapy era: a longitudinal cohort study	Anke Bruns (UMC Utrecht)	12:50 - 13:00	O.12 Reconstructing the 2022 mpox outbreak among MSM in the Netherlands: Insights into transmission dynamics by HIV status	Jacob Roberts (UMC Utrecht)	12:50 - 13:00	O.18 Comparing a Nanobody-Based Anti-Capsid Biological and Lenacapavir as Intracellular Capsid Inhibitors to Block HIV-1 Replication	Florence Stel (Amsterdam UMC)
13:00 - 14:45	<b>Lunch and poster viewing (105 min)</b>							
13:30 - 14:00	First posterwalk moderated by: Remko van Leeuwen (Aidsfonds) & Kaj Jonas (Maastricht University)							
14:05 - 14:35	Second posterwalk moderated by: Ard van Sighem (SHM) & Jori Symons (UMC Utrecht)							

## Session 3: Paradigm Shifts and Breakthroughs in HIV science

Chairs: Birgit van Benthem (RIVM) & Marit van Gils (Board Stichting NCHIV)

14:45 - 15:20	Plenary "Prevent, treat, or cure: emerging paradigms in HIV and STI" and Q&A	<b>Maximazaal</b>
15:20 - 15:35	Top 5 Clinical papers	prof. dr. Maarten Schim van der Loeff (GGD Amsterdam & Amsterdam UMC) Casper Rokx (Erasmus MC)
15:35 - 15:50	Top 5 Epidemiology papers	Janneke van de Wijgert (UMC Utrecht)
15:50 - 16:05	Top 5 Basic Science papers	Leanne Helgers (Amsterdam UMC)
16:05 - 16:35	<b>Refreshment break</b>	<b>Marble Hall</b>

## Session 4: NCHIV 2025's Top Science in a Changing Political Landscape

Chairs: Peter Reiss (Board Stichting NCHIV) & Jet Gisolf (Rijnstate)

16:35 - 16:45	Top clinical & sociobehavioural science abstract O.19 Baseline resistance to cabotegravir and rilpivirine in participants with newly diagnosed HIV-1, ATHENA cohort 2015-2024	Noga Shalev (SHM)
16:45 - 16:55	Top basic / translational science abstract O.20 Characterization of germinal center B-cell responses to the ConM.SOSIP.V7 HIV-1 vaccine candidate suggests diversification of antibody responses after boost vaccination	Laura Graus (Amsterdam UMC)
16:55 - 17:05	Top epidemiology & public health abstract O.21 The PEPFAR Impact Counter experience: Turning data into advocacy in a political crisis	Brooke Nichols (AIGHD)
17:05 - 17:15	Presentation of Joep Lange & Jacqueline van Tongeren Junior Investigator Award and NCHIV Best Poster Award	Board Stichting NCHIV
17:15 - 18:00	Panel discussion Caught Between Politics and Progress: Safeguarding Rights-based HIV Research (session to be conducted in Dutch)  Panellists: Bas Erlings (Oud campagnestrategie VVD, mede-eigenaar Sue & the Alchemists en auteur van de bestseller "Het spel van de populist") Dinah Bons (juridisch en maatschappelijk belangenbehartiger hiv vereniging nederland) prof.dr. Marcel Levi (voorzitter van de NWO, hoogleraar Inwendige Geneeskunde bij Amsterdam UMC/UvA en Professor of Medicine bij University College London) prof.dr. Rogier Sanders (hoogleraar virologie, i.h.b. experimentele vaccinologie, Amsterdam UMC/UvA)	Moderator: Coen Verbraak (historicus, journalist en programmamaker)
18:00 - 19:00	<b>Drinks</b>	<b>Marble Hall</b>